Ratio Therapeutics and RayzeBio have entered into a research collaboration and license agreement to advance a novel radiopharmaceutical programme focused on two undisclosed targets.  Under the terms of the agreement, Ratio will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments, as well as royalties on net sales.   The […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!